Editas Medicine (EDIT) Tops Q2 EPS by 2c

Editas Medicine (NASDAQ: EDIT) reported Q2 EPS of ($0.81), $0.02 better than the analyst estimate of ($0.83).

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• Oracle raises full year profit guidance, stock rises after hours
• Zumiez, Inc. (ZUMZ) Misses Q2 EPS by 6c, Misses on Revenue; Offers Q3 Guidance